Knowledge Hub

Hypertrophic Cardiomyopathy - Pipeline Review, H1 2016

Press Release   •   Oct 28, 2016 05:13 EDT has recently announced the addition of a market study “ Hypertrophic Cardiomyopathy - Pipeline Review, H1 2016 ”, is a comparative analysis of the global market.

Hypertrophic Cardiomyopathy - Pipeline Review, H1 2016


Global Markets Directs, Hypertrophic Cardiomyopathy - Pipeline Review, H1 2016, provides an overview of the Hypertrophic Cardiomyopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Download The sample Copy Of This Report:


- The report provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy

- The report reviews pipeline therapeutics for Hypertrophic Cardiomyopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Hypertrophic Cardiomyopathy therapeutics and enlists all their major and minor projects

- The report assesses Hypertrophic Cardiomyopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hypertrophic Cardiomyopathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hypertrophic Cardiomyopathy Overview 6

Therapeutics Development 7

Pipeline Products for Hypertrophic Cardiomyopathy - Overview 7

Pipeline Products for Hypertrophic Cardiomyopathy - Comparative Analysis 8

Hypertrophic Cardiomyopathy - Therapeutics under Development by Companies 9

Hypertrophic Cardiomyopathy - Therapeutics under Investigation by Universities/Institutes 10

Hypertrophic Cardiomyopathy - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Hypertrophic Cardiomyopathy - Products under Development by Companies 13

Hypertrophic Cardiomyopathy - Products under Investigation by Universities/Institutes 14

Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development 15

Gilead Sciences, Inc. 15

Heart Metabolics Limited 16

miRagen Therapeutics, Inc. 17

MyoKardia, Inc. 18

Hypertrophic Cardiomyopathy - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 25

Drug Profiles 27

eleclazine - Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

HCM-2 - Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

MGN-9103 - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

MYK-461 - Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

perhexiline maleate - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

ranolazine ER - Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small Molecule for Cardiac Hypertrophy - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Hypertrophic Cardiomyopathy - Recent Pipeline Updates 38

Hypertrophic Cardiomyopathy - Dormant Projects 42

Hypertrophic Cardiomyopathy - Discontinued Products 43

Hypertrophic Cardiomyopathy - Product Development Milestones 44

Featured News & Press Releases 44

May 02, 2016: MyoKardia Receives Orphan Drug Designation for MYK-461 for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy 44

Mar 15, 2016: Heart Metabolics Announces Multiple Senior Appointments to Management Team 44

Feb 04, 2016: MyoKardia Publishes Article in Science Demonstrating That MYK-461 Prevents and Reverses Disease in Genetic Mouse Models of Hypertrophic Cardiomyopathy 45

Oct 06, 2015: MyoKardia Provides Update on Two Phase 1 Trials of MYK-461 for the Treatment of Hypertrophic Cardiomyopathy 46

Apr 15, 2015: Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy 46

Mar 03, 2015: MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy 47

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50